Trodelvy's clinical development in China, led by Everest Medicines, follows the agent's US accelerated approval in April for triple-negative breast cancer.
The research showed that atezolizumab plus nab-paclitaxel provided survival benefits, as did an antibody-drug conjugate that was recently approved by the FDA.
